Pursuant to Regulation 34 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 please find enclosed the Notice of Extraordinary General Meeting to be held on 12/June/2025 ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma has called an Extraordinary General Meeting on 12 June 2025 at 3:00 p.m. via video conferencing to seek shareholder approval on 14 resolutions. Two key resolutions seek to raise the company's borrowing limit and its authority to create charges on assets up to Rs. 2,500 crores each, replacing earlier limits set in 2019 and 2023. The remaining 12 resolutions seek approval for material related party transactions with various group companies and subsidiaries — including Sudarshan Pharma Industries Singapore (Rs. 500 cr), Ratna Lifesciences (Rs. 100 cr), Ishwari Healthcare (Rs. 50 cr), Sudarshan Solvents (Rs. 50 cr), Sudarshan Maven Pharma, Sachin Chemsolve, Magicremedi (Rs. 25 cr each), Life Science Chemical, Sudarshan Capital, Sudarshan Pharma Lifescience, Sudarshan Chempharma India LLP, and Sudarshan Akshar Specialty Chemicals LLP (Rs. 10-15 cr each). All related party transactions are stated to be at arm's length and in the ordinary course of business.
These are primarily housekeeping authorizations — pre-approving borrowing capacity and related party deal limits that the company intends to use over the coming year. Shareholders should review the explanatory statement and assess the scope of related party dealings (totalling over Rs. 800 crores in aggregate limits) and the significant rise in borrowing headroom before voting at the EGM.